Osilodrostat therapy in a 26-year-old patient after ineffective surgical treatment of Cushing Disease: a case report

Magdalena Kamińska¹, Adam Strzoda¹, Agata Juda¹, Kornelia Rojek³, Anna Strzoda¹, Wojciech Sowiński¹, Agnieszka Polak²

¹ Student Scientific Society at Department of Endocrinology, Diabetology and Metabolic Diseases, Medical University of Lublin, Kazimierza Jaczewskiego 8, 20-400 Lublin, Poland
² Department of Endocrinology, Diabetology and Metabolic Diseases, Medical University of Lublin, Kazimierza Jaczewskiego 8, 20-400 Lublin, Poland
³ Magdalena Kamińska: https://orcid.org/0000-0002-7624-4146 e-mail: mkaminska99@gmail.com
Adam Strzoda: https://orcid.org/0000-0002-1928-2664 e-mail: adamanstrzoda@gmail.com
Agata Juda: https://orcid.org/0000-0003-3583-7305 e-mail: agatajuda15@gmail.com
Kornelia Rojek: https://orcid.org/0000-0002-5096-1235 e-mail: rojekkornelia@gmail.com
Anna Strzoda: https://orcid.org/0000-0002-4839-3531 e-mail: annastrzoda2000@gmail.com
Wojciech Sowiński: https://orcid.org/0000-0002-2267-4773 e-mail: wojciechjansowski@gmail.com
Agnieszka Polak: https://orcid.org/0000-0003-1694-4738 e-mail: agnieszka.polak@icloud.com

Abstract

Cushing’s Disease is caused by pituitary adenoma which produces adrenocorticotropic hormone causing hypercortisolismia. First-line treatment involves operative removal of the tumor, however, in some patients it proves ineffective. In those cases, pharmacological treatment is necessary as untreated Cushing’s Disease may be lethal. In 2020 a new steroidogenesis inhibitor – Osilodrostat - was approved by the European Medicines Agency and can be used in the treatment of patients who cannot undergo pituitary surgery or whose previous surgical treatment proved ineffective. We present a case of a 26-year-old female patient who was diagnosed with endogenous Cushing’s Disease and underwent two consecutive operations to remove the tumor - both were ineffective. With deteriorating laboratory results and other pharmacological treatments exhausted Osilodrostat therapy was introduced. Osilodrostat is becoming an important drug in patients with Cushing’s Disease refractory to other treatments.

Key Words: ACTH-dependent Cushing syndrome; Osilodrostat; Steroidogenesis Inhibitor.

Introduction

Cushing’s disease (CD) is a rare endocrinological disorder with hypercortisolismia caused by the excess of adrenocorticotropic hormone (ACTH) produced by the pituitary adenoma. (1) Normally ACTH is released from the pituitary gland and induces cortisol production by the adrenal glands. The excess of ACTH produced outside the pituitary gland results in Cushing syndrome (CS). (2) In disorders mentioned above symptoms such as central obesity (moon face, buffalo hump), muscle atrophy of the limbs, red stretch marks on the abdomen, thighs, breasts, and arms, hirsutism and facial plethora can be observed. (3) Based on epidemiological studies in Europe the incidence of CD is approximately 2.4 per million inhabitants per year. (3) Without treatment the 5 years survival of patients with CD is around 50%. (4) The presented case pertains to a 26-year-old woman who was diagnosed with ACTH-dependent Cushing syndrome and was treated with Osilodrostat (Isturisa) due to a poor response to other therapeutic methods.

203
Case report
We report on a 26-year-old female patient who was referred to the Department of Endocrinology with suspicion of Cushing's Syndrome. Symptoms reported by the patient and observed on admission included hypertension (up to 160/110 mmHg) with co-existing headaches, amenorrhea (for 6 months), wide, red stretch marks on the abdomen, weight loss, hair loss, and rounding of the face. (Figure 1)

![Figure 1 Symptoms noticed during admission - red stretch marks on the abdomen and hair loss](image)

Pre-admission laboratory results indicated hyperemia (Hb=17 g/dL, RBC= 5.33x10⁶/μL, Ht=53%), showed elevated testosterone (115 ng/dL), dehydroepiandrosterone sulfate (DHEA-S) (1171 μg/dL), and morning cortisol (420 ng/mL). The patient had a history of premature puberty (~10 years of age).

The dexamethasone suppression test (DST) with 8 mg of Dexamethasone revealed no decrease in cortisol in the serum. In the corticotropin-releasing hormone (CRH) stimulation test after 15 minutes, ACTH levels rose from 47 pg/mL to 72 pg/mL and cortisol rose from 30 µg/dL to 34 µg/dL. In laboratory findings, elevated levels of testosterone, androstenedione, and liver enzymes were observed alongside hypernatremia and hypokalemia. Because of high cortisolemia, Ketoconazole treatment was started with a dose of 1000 mg/day. Due to contradictory results of the DST and CRH stimulation test a pituitary magnetic resonance imaging (MRI) was taken. The pituitary gland was not enlarged with no features of microadenoma. To exclude the ectopic secretion of ACTH a positron emission tomography scan (PET) was taken. In the meantime, Ketoconazole was changed to Metyrapone in a daily dose of 1500 mg which was then enlarged to 2000 mg and later 2500 mg with good results - a significant decrease of cortisol in serum and normalization of its excretion in a 24-hour urine collection. On account of no conclusive findings in imaging tests (Figure 2), inferior petrosal sinuses sampling (IPSS) was performed, which confirmed ACTH-dependent hypercortisolemia of pituitary origin.

![Figure 2 Pituitary imaging (PET CT - left image, CT - right image) with the possible location of the tumor pointed by the red arrow](image)
The patient underwent two consecutive pituitary adenoma operations through the sphenoid sinus. Post-operative levels of cortisol and ACTH were long-term elevated and surgical treatment proved ineffective. Due to the adversary effects of previous treatment – elevated testosterone levels, and androgenization symptoms a decision to use combined therapy using Pasireotide, Ketoconazole and Cabergoline was made. However, this therapy was insufficient - cortisol in serum and urine remained strongly elevated despite maximal doses. On this ground, a steroidogenesis inhibitor - Osilodrostat was prescribed. The patient received a starting dose of 4 mg/day which was consequently risen to 10 mg, 16 mg, and ultimately to 30 mg per day. The Osilodrostat therapy at first brought a significant decrease in cortisol levels in serum and cortisol excretion in a 24-hour urine collection was only slightly elevated. Unfortunately, later the drug seemed to be less successful the levels of cortisol in serum and in urine fluctuated as well as testosterone remained elevated and the patient noticed the exacerbation of androgenization symptoms. As of today, the patient remains under endocrinological care with continuous evaluation of treatment and its effects.

Discussion
When diagnosing a patient with hypercortisolemia the first step is to distinguish ACTH-dependent from independent CS. Standard procedures determining the type of CS are morning ACTH levels in serum, DST, and CRH stimulation test. Our patient’s laboratory results suggested an ACTH-dependent CS. To confirm the initial diagnosis, imaging tests such as MRI and PET scan were taken as well as IPSS was performed. The latter confirmed decision to operate on the pituitary gland was made as the first-line therapy for patients with CS is an initial resection of the primary lesions. (5) (6) In our patient a surgical removal of the suspected pituitary tumor was performed twice, however soon after the operation the cortisol in serum, as well as ACTH, elevated. With no success in surgical treatment, the patient remained on pharmacological therapy. The first drug introduced to control hypercortisolemia was Ketoconazole (600 mg/day). This antifungal agent inhibits steroidogenic enzymes 11 β-hydroxylase, 17-hydroxylase, and 18-hydroxylase and has an estimated efficacy of 70% in CS treatment. (7)
In our patient’s case, no significant improvement was found after Ketoconazole treatment (Table 1) and Metryrapone was introduced into the therapy with a daily dose of 1500 mg/day.

<table>
<thead>
<tr>
<th>Laboratory parameters</th>
<th>Reference range</th>
<th>Admission</th>
<th>Ketoconazole initiation (600 mg per day)</th>
<th>Ketoconazole highest dose (1000 mg per day)</th>
<th>Metryrapone initiation (1500 mg per day)</th>
<th>Metryrapone highest dose (2500 mg per day)</th>
<th>Pasireotide, Ketoconazole, Cabergoline</th>
<th>Osilodrostat initiation (4 mg per day)</th>
<th>Osilodrostat highest dose (30 mg per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTH [pg/mL]</td>
<td>7.20 – 63.60</td>
<td>50.27</td>
<td>72.72</td>
<td>82.71</td>
<td>73.81</td>
<td>48.15</td>
<td>172.10</td>
<td>88.06</td>
<td>249.30</td>
</tr>
<tr>
<td>Cortisol in serum [µg/dL]</td>
<td>4.30 – 22.40</td>
<td>24.40</td>
<td>34.40</td>
<td>29.20</td>
<td>49.10</td>
<td>42.20</td>
<td>49.10</td>
<td>39.50</td>
<td>24.02</td>
</tr>
<tr>
<td>Cortisol in urine [µg/24h]</td>
<td>20.90 – 292.30</td>
<td>635.50</td>
<td>876.30</td>
<td>430.10</td>
<td>577.50</td>
<td>525.00</td>
<td>577.50</td>
<td>869.00</td>
<td>433.40</td>
</tr>
<tr>
<td>Testosterone [ng/dL]</td>
<td>12.0 – 59.0</td>
<td>77.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>52.00</td>
<td>212.10</td>
</tr>
<tr>
<td>Androstenedione [ng/mL]</td>
<td>0.4 – 3.4</td>
<td>3.53</td>
<td>1.01</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>25.96</td>
<td></td>
</tr>
<tr>
<td>(DHEA-S) [µg/dL]</td>
<td>98.80 – 340.00</td>
<td>920.70</td>
<td>-</td>
<td>431.20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1 Laboratory parameters on various types of medication**

Metryrapone is an inhibitor of 11 β-hydroxylase and blocks the last stage of steroidogenesis. The effectiveness of Metryrapone therapy in CS reaches 75%. A rare complication of Metryrapone therapy is a compensatory increase in ACTH production resulting from a decrease in cortisol-mediated negative feedback on the corticotropic adenoma which may lead to an increase in cortisol and androgens production. (8,9) This compensatory mechanism could explain elevated testosterone which was noticed on a follow-up. During Metryrapone treatment, our patient had the best results with lowered urinary-free cortisol (UFC) and serum cortisol, however, androgenization syndromes as well as episodes of hypertension prompted the physicians to change the treatment.
A combined therapy using Pasireotide, Ketoconazole, and Cabergoline was initiated. In a study of patients with severe CD, the combination normalized UFC levels in 67% of patients. (10) Pasireotide is a somatostatin analog that is the only pituitary-directed drug approved in the EU for CS treatment aimed to decrease ACTH levels as well as cortisol levels in serum and urine. (11) Unfortunately, in our patient, the levels of cortisol in urine remained strongly elevated, however it has decreased ACTH and cortisol levels in serum. Cabergoline is another drug used in this treatment. It has a high affinity for dopamine 2 receptors (D2Rs), which are commonly expressed in 80% of human corticotroph tumors. (11) It was used in hope of minimizing the size of the pituitary tumor and consequently resolving the metabolic symptoms of CD, however it remained ineffective. With no other therapeutic options available, Osilodrostat therapy was initiated.

Osilodrostat is a novel 11-β-hydroxylase and aldosterone synthase inhibitor, approved by the European Medicines Agency in 2020 for the treatment of endogenous CS. It has been used in the treatment of patients who cannot undergo pituitary surgery or whose previous surgical treatment proved ineffective. (12) It is an oral nonsteroidal corticosteroid inhibitor with three times higher affinity than Metyrapone. In addition, in comparison to Metyrapone lower doses of Osilodrostat may be sufficient to reach the same effects on cortisol levels. Osilodrostat has also a longer half-life than Metyrapone, which allows less frequent dosage. (6) In our patient the first 12 weeks of the therapy with Osilodrostat resulted in a decrease in UFC and cortisol in serum by nearly 50% (Tables 2 and 3), now a raise in both parameters is observed.

![Cortisol in serum amendment during treatment [μg]](image)

*Table 2 Amendment of cortisol in serum during treatment. The red color indicates results during Osilodrostat therapy*
The fluctuance in the levels of cortisol in serum and urine in our patient during Osilodrostat therapy is not coherent with most studies where after 22 weeks nearly 80% of the patients have mean urinary cortisol within the normal range. (6)(13) Some studies on animal models suggest good results in a combined Pasireotide and Osilodrostat therapy, however, no studies on humans were conducted, and possible adversary effects are expected. (14)

In most of the patients during clinical trials of Osilodrostat monotherapy, improvements in parameters such as body weight, fasting plasma glucose, and blood pressure were observed. (15) Also at least one physical feature of CS such as central obesity (moon face), muscle atrophy of the limbs, red stretch marks and facial plethora has improved in over 25% of examined, buffalo hump improvement was observed in over 50% of patients during Osilodrostat treatment. (15) Alleviation of some CD symptoms was reported by our patient - weight loss and decrease in hair loss. On the other hand, Osilodrostat can cause hypokalemia, QTc prolongation, and hypertension. (16) Fortunately none of the symptoms above were observed in our patient during Osilodrostat therapy. Moreover, patients on Osilodrostat therapy may have elevated testosterone levels which cause hirsutism, acne and secondary amenorrhea, which were observed in our patient throughout the treatment. (17) For those reasons hormone replacement therapy was introduced by the gynecologist. However, it was decided to continue the Osilodrostat treatment since the elevated testosterone levels are reported to be transient in other patients treated with this oral nonsteroidal corticosteroid inhibitor. (13,16) To this day we continue to treat our patient with Osilodrostat, due to the lack of other options, since the pros outweigh the cons, however, we are aware that the patient's affliction is floating and the alteration in treatment is likely. Higher doses of Osilodrostat might be necessary, on the other hand, more adversary effects are expected. A combined therapy using Ketoconazole (dose 600 mg/day) and Osilodrostat (30 mg/day) appears promising. That combination was reported to be highly effective in terms of cortisol secretion. Additionally lower doses than those applied in monotherapy were used which minimized the adversary effects previously observed in a single therapy. (18) However to our knowledge it was a single case stated in literature treated using this combined therapy and further data considering this treatment are awaited.

Conclusions
CD is a severe condition that left untreated deteriorates life quality and may be life-threatening. With no improvements after the first-line operative approach, our patient was treated with various medicaments including a novel nonsteroidal corticosteroid inhibitor of the 11-ß-hydroxylase and aldosterone synthase – Osilodrostat. To this day the anticipated laboratory and clinical results (physical symptoms, cortisol in serum and in urine) were not met and alteration of the treatment might be necessary.

Disclosure
The authors declare no conflict of interest.
References